A 42-year-old woman from Tamil Nadu with lepromatous leprosy has completed 12 months of WHO multidrug therapy (MDT) with rifampicin, dapsone, and clofazimine. Skin smear microscopy now shows no acid-fast bacilli. She reports persistent brownish-black discoloration of skin and conjunctivae that developed during treatment. She is concerned about the cosmetic appearance. What is the most appropriate next step?